JP2024524273A5 - - Google Patents

Info

Publication number
JP2024524273A5
JP2024524273A5 JP2023579334A JP2023579334A JP2024524273A5 JP 2024524273 A5 JP2024524273 A5 JP 2024524273A5 JP 2023579334 A JP2023579334 A JP 2023579334A JP 2023579334 A JP2023579334 A JP 2023579334A JP 2024524273 A5 JP2024524273 A5 JP 2024524273A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
weeks
week
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/100878 external-priority patent/WO2022268174A1/zh
Publication of JP2024524273A publication Critical patent/JP2024524273A/ja
Publication of JP2024524273A5 publication Critical patent/JP2024524273A5/ja
Pending legal-status Critical Current

Links

JP2023579334A 2021-06-25 2022-06-23 マズチドの使用 Pending JP2024524273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110711050.0 2021-06-25
CN202110711050 2021-06-25
PCT/CN2022/100878 WO2022268174A1 (zh) 2021-06-25 2022-06-23 Mazdutide的应用

Publications (2)

Publication Number Publication Date
JP2024524273A JP2024524273A (ja) 2024-07-05
JP2024524273A5 true JP2024524273A5 (https=) 2025-06-30

Family

ID=84544128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579334A Pending JP2024524273A (ja) 2021-06-25 2022-06-23 マズチドの使用

Country Status (9)

Country Link
US (1) US20240293513A1 (https=)
EP (1) EP4360641A4 (https=)
JP (1) JP2024524273A (https=)
KR (1) KR20240027053A (https=)
CN (1) CN117597135A (https=)
AU (1) AU2022298841A1 (https=)
CA (1) CA3224043A1 (https=)
TW (1) TW202300171A (https=)
WO (1) WO2022268174A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법
WO2025073289A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2025073288A1 (en) * 2023-10-03 2025-04-10 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
CN120676965A (zh) * 2023-11-07 2025-09-19 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
KR20250021331A (ko) * 2022-06-01 2025-02-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 mazdutide를 사용하는 치료 방법

Similar Documents

Publication Publication Date Title
JP2024524273A5 (https=)
JP2010525078A5 (https=)
US20200360324A1 (en) Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases
CN1178696C (zh) 含人体生长激素和皮质甾醇合成抑制剂的用于治疗代谢综合症的制剂
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
JP2019515884A5 (https=)
CN113301889A (zh) Nafld和nash的联合治疗
TWI908718B (zh) 類鐸受體促效劑給藥方案
JP2022533981A5 (https=)
US20210260025A1 (en) Capsid assembly modulator dosing regimen
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
JP2022533968A5 (https=)
JP2018532797A5 (https=)
JP2022554276A5 (https=)
JPWO2023054732A5 (https=)
MX2014000971A (es) Agente mejorador de la funcion diastolica ventricular izquierda.
BRPI0610873A2 (pt) tratamento de doenças hepáticas em que o ferro desempenhe um papel na patogênese
CN113784717A (zh) 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
JP2024527023A5 (https=)
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP2024520020A5 (https=)
JP2023502053A5 (https=)
JP2006524190A5 (https=)
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
DK166343B (da) Forbedret piroxicamholdigt laegemiddel